The FDA has approved a new drug called zolbetuximab designed to attack a novel target that’s in a type of stomach cancer.
Marketed under the brand name Vyloy, the drug is to be used with fluoropyrimidine- and platinum-based chemotherapy in adults with advanced cancer of the stomach or gastroesophageal junction that’s positive for claudin 18.2 , a protein that promotes tumor growth and spread. Vyloy is the first drug in the United States that targets this protein.
“While there have been advances in the first-line treatment of locally advanced unresectable and metastatic gastric and GEJ cancers in the last several years, there is still a tremendous unmet need among our patients,” Samuel J. Klempner, MD, a cancer specialist at Massachusetts General Hospital, Boston, and an associate professor at Harvard Medical School, said in a. The approval “brings forward a novel biomarker and new therapy for patients whose tumors are CLDN18.
The treatment is intended for patients with HER2-negative gastric or GEJ adenocarcinoma that has either spread or cannot be removed by surgery. In clinical trials, about 38% of these patients were found to be CLDN18.2-positive. The FDA also approved the VENTANA CLDN18 RxDx Assay, a test to detect CLDN18.2-positive tumors and confirm eligibility for the new treatment.
The approval was based on results of two international phase III clinical trials including 567 and 507 patients. The trials added Vyloy to two different chemotherapy regimens. In one trial, patients who took Vyloy with chemotherapy went 10.6 months without the cancer worsening, compared with 8.7 months for those who took a placebo. The addition of Vyloy also improved overall survival by about three months. Patients in the other trial on chemotherapy saw similar results – those on Vyloy went 8.2 months without cancer worsening, compared to 6.8 months with chemotherapy alone. The overall survival benefit was about two months., and fever.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
New Drug Class for Prurigo Nodularis Moving ForwardTwo years after the first therapy for prurigo nodularis was approved, an oral drug in clinical trials provides a third mechanism of action for treating this disease.
Read more »
Seattle first city to equip first responders with opiate overdose drug BuprenorphineSeattle is the first city with first responders equipped and allowed to administer the opioid use disorder drug, Buprenorphine.
Read more »
Chargers rookies are making new GM's first draft class a smash hitBecause of a slew of injuries in the Chargers secondary, rookie corners Cam Hart and Tarheeb Still were propelled into the starting lineup and have done well.
Read more »
FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in decadesThe twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S. living with schizophrenia.
Read more »
FDA Approves First New Schizophrenia Drug in Over 30 YearsThe FDA has approved Cobenfy, a new drug developed by Bristol Myers Squibb, to treat schizophrenia. This marks the first new treatment for the condition in over three decades.
Read more »
FDA Approves First New Schizophrenia Drug in 30 YearsThe U.S. Food and Drug Administration (FDA) has approved Cobenfy, the first new drug to treat schizophrenia in over three decades. Manufactured by Bristol Myers Squibb, Cobenfy combines xanomeline and trospium chloride and is taken as a twice-daily pill. Clinical trials showed it effectively managed symptoms such as hallucinations, delusions, and disorganized thinking.
Read more »